Applying a Novel Approach to Modulating
NMDA Receptors to Develop Improved CNS Therapies
-
Overview:
-
Naurex has discovered a novel way of modulating NMDA receptors via a new mechanism of action called Glycine-site Functional Partial Agonists (GFPAs), which are designed to achieve the strong efficacy of classic NMDA modulators without their limiting CNS side effects
Learn more…
-
Our Mission:
Naurex is developing its novel GFPA drug platform and programs to treat multiple CNS diseases including depression, cognitive disorders, schizophrenia and neuropathic pain.
Learn more…
First clinical target: Treatment-resistant depression



